Why I recommend continuing to use the MINI on paper in clinical studies.

1. The MINI has only been validated on paper. E-versions require separate validation To my knowledge the MINI has only been validated in its original paper format. This matters because regulatory authorities like the Food and Drug Administration (FDA ) and the European Medicines Agency (EMA) require CDS tools to be separately and  independently validated in each medium in which they are used to ensure their accuracy, reliability, and safety. Importantly,
   • Validation of the MINI on paper is not, as some might think, automatically transferrable to electronic versions. In different words, just because the MINI is validated on paper doesn’t mean that it is validated in any e-version. This is a significant drawback since each e-version, whether for the web, a tablet or handheld, must undergo its ownfit-for-purpose validation, including software verification and usability testing.
   • Further, per FDA’s 2024 Guidance (Q7), sponsors and CROs are responsible not just for initial validation of any e-version of a CDS tool like the MINI or a variant of the MINI, but also for ongoing lifecycle validation, depending on system’s risk. This adds significant time, cost, and regulatory burden.
   • eCOAs, ClinROs, and digital CDS tools must also comply with FDA Chapter 21, Part 11 Code of Federal Regulations (21 CFR Part 11) and / or European Medicines Agency (EMA) Guidelines for Good Clinical Practice (GCP Annex 2) expectations and failure to validate properly can compromise data integrity and trial credibility
2. Administering the MINI is easier on paper. Many of the MINI’s disorder modules have items that require consulting responses in other modules before a disorder can be documented and confirmed. This is a straightforward task on paper since you can easily turn back to previous pages and view both simultaneously. Not so on a device such as a laptop, tablet or smartphone that only allows you to view one window at a time and navigating back to a previous window may require starting the app all over again while trying to remember where you were and what the question was that you need to check. This task is compounded if the app freezes or there are system failures or loss of internet access or electrical power.
3. The risk of diagnostic error (misdiagnosis) is lower for paper. The accuracy of the MINI depends on careful application of its skip logic and algorithms, a process that is visible and easy to follow on paper. Raters can see the coding directions. They can go back and check to make sure they followed the directions, and they can self-correct if needed. Supervisors and auditors can also more easily do this. This is much more difficult on e-versions where the risk of error is heightened for 3 reasons:
   • Coding the MINI’s complex algorithms for use on electronic devices and systems (not to mention updating the coding every time the operating system has an update) requires rare expertise in both programming and DSM-based clinical logic.
   • Systematic error in codingcan have cascade effects, leading to widespread misdiagnosis across multiple modules. Even one mistake, e.g. in the programming code for Major Depressive Disorder (MDD), a disorder diagnosis that depends on responses in a multiplicity of modules, can have a multiplier effect resulting in misdiagnoses of more than one disorder.
   • The logic is not visible to the rater. Errors are hidden from view, under the screen, making it difficult (virtually impossible) for raters to detect them or correct them in real time.
4. Regulatory compliance is simpler. Using the MINI on paper avoids costly, complex, and time-consuming regulatory hurdles that come with digitizing clinical decision support (CDS) tools like the MINI. For example:
   • CDS tools specifically used to “diagnose” or “inform clinical decisions” in fragile populations (e.g., psychotic patients) or those in critical “life threatening” situations (e.g. suicidal patients) may be classified as Software as a Medical Device (SaMD)— triggering FDA 510(k) premarket review and International Medical Device Regulators Forum (IMDRF) compliance. This can delay a trial launch by months.
   • Many eCOA platforms require additional validation under FDA Computer System Validation (FDA CSV) and European Union European Union Good Manufacturing Process (EU GAMP) frameworks to be compliant and avoid risk.
   • Chapter 21, Part I Code of Federal Regulations (21 CFR Part 11) requires robust audit trails, backup protocols, and system validation. These are difficult and costly to implement for complex diagnostic tools like the MINI, especially across multiple device types (e.g., the web, tablet, mobile applications).
   • Institutional Review Boards (IRBs) often require screenshots of every screen and format to ensure e-versions match the approved paper tool — creating potential IRB delays and approval bottlenecks.
   • As mentioned earlier, as of 2024 FDA Guidance, eCOA versions of instruments like the MINI need to undergo separate validation since paper-based validation does not transfer. Each version for each platform use (tablet, smartphone, browser) must be independently verified and documented.
   • Both Health Insurance Portability and Accountability Act (HIPAA) and General Data Protection Regulation (GDPR)impose stricter security and privacy requirements on eCOAs, especially when they are used across cloud-based or mobile systems — increasing sponsor liability.
   • For translations, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) standards and FDA require new linguistic validation for each electronic format, not just reuse of certified paper translations.

Bottom line:
If you use an eCOA to document a DSM diagnosis and that eCOA is not independently validated, 21 CFR Part 11 compliant, 510(k), cleared as a medical device, linguistically re-certified, and platform-verified, it may not meet regulatory expectations — risking trial delays, rejections, or non-acceptance of data. Paper versions avoid these complexities and their associated costs.

5. Subjects have fewer privacy concerns. Trial subjects are often and rightfully fearful that sensitive data, especially mental health data, entered online on the web or an app can be hacked, sold, or shared to 3^rd party vendors over the web or accessed by governments. This is not a concern with paper versions of the MINI that can be securely stored under lock and key.
6. The presence of digital devices may reduce patient comfort and disclosure, undermining rapport and the integrity of the clinical interaction with consequent effects on data.
7. Data protection, preservation and retention are easier on paper. You don’t need to worry about system crashes or freezes or cybersecurity threats. Additionally, you can retain your records on paper under lock and key for as long as required by regulators, usually 10 years and sometimes indefinitely, without fussing about how changes or updates to operating systems affect file format, storage access and retrieval. In contrast, digital systems if not continuously maintained and secured are at risk of data loss from cyberattacks, phishing, data leakage, identity theft, and fraud, or accidental or unintentional deletion of data. Paper records can be maintained without these risks.
8. Auditing is an easier, less complex task with paper versions. Keeping an audit trail, as required by the FDA, EMA, and other regulatory bodies, is more straightforward when the MINI is administered on paper. That’s because the algorithms required to make disorder diagnoses are visible and can easily be checked by the rater, a supervisor and / or auditor on the paper version. This is much more challenging on e-versions where searchable audit trails to capture changes (modifications or deletions on records) require sophisticated programming to comply with regulatory guidance such as Part 11 21 CFR and the audit path may not be transparent to the user.
9. More translations are available for paper versions of the MINI. Upwards of 70 linguistically validated language translations, approved by me, the copyright holder, are available in paper format for studies and trials. These translations and their associated language certifications are not automatically transferrable to e-versions. That’s because e-versions always require adaptations for screen usage. Further, per FDA, EMA, and International Society for Pharmacoeconomics and Outcomes Research (ISPOR) translation standards, the adapted versions may require evidence from the sponsor of translation accuracy and equivalence, often via linguistic validation, in each medium in which eCOA are used. This is a time-consuming and expensive process that could mean forward and back translation within each medium or device. Also, language certifications of paper versions do not apply to e-versions which have their own independent verification and certification processes.
10. Costs are lower for the paper version of the MINI. Implementing a diagnostic interview like the MINI in formats other than paper can be a costly and time intensive undertaking because of the number of modules and items to code and the sophistication required to implement the algorithms. These costs, passed on to the sponsor, are compounded if implementation is planned across a multiplicity of platforms e.g., the web, tablets, mobile devices, with different system requirements. In addition, sponsors incur other indirect costs in the form of enhanced regulatory oversight.

For more information on the MINI review our FAQs

Disclaimer: This article is for educational purposes and does not constitute medical, legal or regulatory advice. Always consult with regulatory experts before implementing the MINI in clinical trials or digital health applications.

To license the MINI or MINI-Kid directly from the copyright holder, consult with Dr. Sheehan or obtain training on the use of the MINI, go to DASH Neuroscience.

Table of Abbreviations